- Home
- EBC vs AKRO Comparison
EBC vs AKRO Comparison
Compare EBC & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBC
- AKRO
- Stock Information
- Founded
- EBC 1818
- AKRO 2017
- Country
- EBC United States
- AKRO United States
- Employees
- EBC N/A
- AKRO N/A
- Industry
- EBC Accident &Health Insurance
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- EBC Finance
- AKRO Health Care
- Exchange
- EBC Nasdaq
- AKRO Nasdaq
- Market Cap
- EBC 3.5B
- AKRO 3.9B
- IPO Year
- EBC 2020
- AKRO 2019
- Fundamental
- Price
- EBC $15.00
- AKRO $49.65
- Analyst Decision
- EBC Buy
- AKRO Strong Buy
- Analyst Count
- EBC 2
- AKRO 8
- Target Price
- EBC $19.25
- AKRO $82.50
- AVG Volume (30 Days)
- EBC 1.2M
- AKRO 1.9M
- Earning Date
- EBC 07-24-2025
- AKRO 05-12-2025
- Dividend Yield
- EBC 3.21%
- AKRO N/A
- EPS Growth
- EBC N/A
- AKRO N/A
- EPS
- EBC N/A
- AKRO N/A
- Revenue
- EBC $457,519,000.00
- AKRO N/A
- Revenue This Year
- EBC $25.36
- AKRO N/A
- Revenue Next Year
- EBC $27.80
- AKRO N/A
- P/E Ratio
- EBC N/A
- AKRO N/A
- Revenue Growth
- EBC N/A
- AKRO N/A
- 52 Week Low
- EBC $12.66
- AKRO $17.86
- 52 Week High
- EBC $19.40
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- EBC 44.99
- AKRO 63.34
- Support Level
- EBC $14.61
- AKRO $44.94
- Resistance Level
- EBC $15.13
- AKRO $49.29
- Average True Range (ATR)
- EBC 0.27
- AKRO 3.33
- MACD
- EBC -0.03
- AKRO 0.67
- Stochastic Oscillator
- EBC 28.06
- AKRO 86.02
About EBC Eastern Bankshares Inc.
Eastern Bankshares Inc is a commercial bank that caters its products and services to retail, commercial, and small business customers. Its diversified products and services include lending, deposit, wealth management, and insurance products. The company has one operating segment; Banking business which offers a range of banking lending, savings, and small business offerings, and its wealth management and trust operations.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.